Kristin Bietz
Nurse Practitioner · Mitchell, SDNPI 1144714205
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,575 of the $1,892 with a category attached, or 83.3%. It is spread thinly across 38 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations.
Across 96 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$243
- AstraZeneca$169
- E.r. Squibb & Sons, L.L.C.$137
- Daiichi Sankyo Inc.$133
- Novartis$115
- Merck$92
- plus $1K from 32 others
What the payments were for
- Food & beverage$1,57583%
- Education$31617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $243 |
| AstraZeneca(2 entities) | 6 | $169 |
| E.r. Squibb & Sons, L.L.C. | 6 | $137 |
| Daiichi Sankyo Inc. | 8 | $133 |
| Novartis | 7 | $115 |
| Merck | 5 | $92 |
| Incyte Corporation | 5 | $86 |
| Exelixis Inc. | 1 | $75 |
| Seagen Inc. | 4 | $71 |
| Gilead(2 entities) | 5 | $69 |
| Bristol Myers Squibb | 3 | $54 |
| Beigene USA, Inc. | 3 | $52 |
| AbbVie | 3 | $49 |
| Genentech USA, Inc. | 3 | $45 |
| Pfizer | 3 | $45 |
| Lilly USA, LLC | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Sanofi | 2 | $24 |
| Immunogen, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $19 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Myovant Sciences Inc. | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Bayer | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Servier Pharmaceuticals LLC | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $15 |
| Morphosys, US Inc. | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| GSK | 1 | $13 |
How this compares
$1,892 in reported general payments places this provider in the 85th percentile of 504 nurse practitioner providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 12 | $149,422 |
| EliquisApixaban | 15 | $9,976 |
| Abiraterone Acetate | 15 | $3,510 |
| Anastrozole | 24 | $424 |
| Hydroxyurea | 29 | $384 |
| Alendronate Sodium | 18 | $365 |
| Prochlorperazine Maleate | 23 | $365 |
| Ondansetron OdtOndansetron | 12 | $264 |
| Letrozole | 14 | $178 |
| Oxycodone Hcl | 11 | $165 |
| Acyclovir | 22 | $147 |
| Levothyroxine Sodium | 16 | $141 |
| Prednisone | 32 | $120 |
| Lorazepam | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $16 | $149,42212 claims |
| PfizerEliquis | $45 | $9,97615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 504 nurse practitioner providers in South Dakota.
Other nurse practitioner in Mitchell
- Jamie BuschSioux Falls$60K
- Jessica SlabaSioux Falls$41K
- Christopher NelsonSioux Falls$35K
- Katherine EricsonSioux Falls$13K
- Rosa EytonAberdeen$7K
- Kristi GlanzerHuron$6K
- Roger DeraadRapid City$6K
- Gabrielle PriceSioux Falls$5K
- Jacqueline KelleySioux Falls$5K
- Jessica YoshinoSioux Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.